ISIS 416858: Phase II started

Isis began a double-blind, placebo-controlled, Canadian Phase II trial to evaluate 200 and 300 mg subcutaneous ISIS 416858 twice weekly for 2 weeks and then once weekly for 10 weeks in about 53 patien...